A component of an enzyme family linked to DNA repair, stress responses, and cancer also plays a role in enhancing or inhibiting major cellular activities under physiological conditions, new research ...

San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase ...

Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

Australian scientists have created a blood test to guide more effective ovarian cancer treatment, by identifying the women more likely to respond to an ovarian cancer treatment known as PARP inhibitor ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...

PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show ...

A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical ...

Results of AFU-GETUG-20: A randomised phase 3 trial of adjuvant androgen deprivation therapy with leuprorelin acetate after radical prostatectomy in patients with high-risk localized prostate cancer.

In the last part of my talk, I'm going to describe three examples of novel therapeutic approaches for the prevention and treatment of diabetic complications, all based on the new paradigm of a ...